The FDA accepted the resubmitted NDA for ataluren, a treatment for nmDMD, without an action date due to a previous complete response letter. Study 041 and the STRIDE registry data support ataluren's ...
Disc Medicine, Inc., a biopharmaceutical company focused on treatments for hematologic diseases, announced positive feedback from its pre-New Drug Application (NDA) meeting with the FDA regarding its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results